IMMITICIDE melarsomine dihydrochloride arsenic heartworm Rx

Issues involving parasite prevention and treatment. Questions, answers, theories, and evidence.
Do pets really need medication every month for worms, fleas and ticks?

IMMITICIDE melarsomine dihydrochloride arsenic heartworm Rx

Postby malernee » Thu Jul 27, 2006 10:11 am

IMMITICIDE® (melarsomine dihydrochloride)
Safety for use in breeding animals and lactating or pregnant bitches has not been determined.
DIN :
ACTIVE INGREDIENT
Melarsomine dihydrochloride is an organic arsenical chemotherapeutic agent. Melarsomine has a molecular weight of 501.34 and is chemically designated as 4 – [(4.6-diamino-1, 3. 5-
triazon-2-yl) amino] phenyl-dithioarsenite of di (2-aminoethyl), dihydrochloride.DOSAGE AND
ADMINISTRATION and PRECAUTIONS).
CONTRAINDICATIONS
IMMITICIDE® is contraindicated in dogs with very severe (Class 4) heartworm disease. WARNING
Keep this and all medications out of the reach of children. Avoid human exposure. Wash hands thoroughly after use or wear gloves. Potentially irritating to eyes. Rinse eyes with copious
amounts of water if exposed. Consult a physician in cases of accidental exposure by any route (dermal, oral, or by injection).
NOTE TO VETERINARIAN
General: All dogs with heartworm disease are at risk for post-treatment pulmonary thromboembolism (death of worms which may result in fever, weakness, and coughing), though
dogs with severe pulmonary arterial disease have an increased risk and may exhibit more severe signs (dyspnea, hemoptysis, right heart failure and possibly death). Dogs should be
restricted from light to heavy exercise post-treatment depending on the severity of their heartworm disease.
Studies in healthy (heartworm negative) dogs indicate that adverse reactions may occur after the second injection in the series even if no problems were encountered with the first
injection. All patients should be closely monitored during treatment and for up to 24 hours after the last injection.
Post-treatment mortality due to thromboembolism and/or progression of the
underlying disease may occur in 10 to 20% of the Class 3 patients treated with IMMITICIDE® (see Mortality). Special Considerations for Older Dogs: In clinical field trials, dogs 8 years or older experienced more post-treatment depression/ lethargy, anorexia/ inappetence, and vomiting than
younger dogs.
SAFETY
IMMITICIDE® has a very low margin of safety. A single dose of 7.5 mg/kg (3X the recommended dose) can result in pulmonary inflammation, edema, and death. Laboratory Studies: In placebo-controlled laboratory studies, IMMITICIDE® administered at 2.5 mg/kg twice, 24 hours apart, was 90.7% effective against transplanted adult
heartworms and 90.8% effective against induced infections of 4 month old (L5) immature heartworms. IMMITICIDE® is provided as: 5 – 50 mg vials of lyophilized melarsomine dihydrochloride with accompanying 5 – 2 mL vials of sterile water for injection U.S.P.
Manufactured at:
BenVenue Laboratories Inc.
Bedford, Ohio 44146
For:
Merial Canada, Inc.
500 Boulevard Morgan
Baie d’Urfé, Québec H9X 3V1
For customer service, adverse reaction reporting, or for a copy of the MSDS, call 1 888-637-4251.
malernee
Site Admin
 
Posts: 462
Joined: Wed Aug 13, 2003 5:56 pm

Return to Parasite Prevention and Treatment

Who is online

Users browsing this forum: No registered users and 0 guests

cron